Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Mazen S. Zenati"'
Autor:
Caroline J. Rieser, David L. Bartlett, Asmita Chopra, Kenneth K.W. Lee, Sowmya Narayanan, Amer H. Zureikat, Alessandro Paniccia, Samer AlMasri, Tracy Daum, Mazen S. Zenati, Katelyn Smith, Nathan Bahary, Vivianne Oyefusi, Ibrahim Nassour
Publikováno v:
J Surg Oncol
BACKGROUND AND OBJECTIVES Neoadjuvant chemotherapy (NAT) for pancreatic adenocarcinoma (PDAC) is increasingly being utilized. However, a significant number of patients will experience early recurrence, possibly negating the benefit of surgery. We aim
Autor:
Alessandro Paniccia, Samer AlMasri, Mohammed Aldakkak, Mazen S. Zenati, Susannah G. Ellsworth, Douglas B. Evans, Kenneth K. Lee, Amer H. Zureikat, A.Y. Hammad, Aatur D. Singhi, Susan Tsai
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:S145
PURPOSE/OBJECTIVE(S) Loss of the tumor suppressor gene SMAD4 is a critical genetic alteration in pancreatic carcinoma (PC). We hypothesized that SMAD4 status in PC is associated with outcomes in patients who received neoadjuvant (NARx) or adjuvant (A
Autor:
Melissa E. Hogg, Amer H. Zureikat, Mazen S. Zenati, Mark D. Girgis, Ahmad Hamad, Jonathan C. King, Herbert J. Zeh
Publikováno v:
Annals of surgery. 274(3)
OBJECTIVE Compare oncologic outcomes after open and robotic pancreatic resections for pancreatic adenocarcinoma (PDAC). SUMMARY OF BACKGROUND DATA Receipt of adjuvant chemotherapy improves survival after resected PDAC. Complications after pancreatect
Autor:
Virginia Falvello, Nathan Bahary, Herbert J. Zeh, Amer H. Zureikat, Ashika Mani, Mazen S. Zenati, Amr I. Al Abbas, Aatur D. Singhi, Melissa E. Hogg
Publikováno v:
Journal of surgical oncologyREFERENCES.
BACKGROUND AND OBJECTIVES Ampullary adenocarcinoma (AA) is classified by immunohistochemical (IHC) subtypes into intestinal (IN), pancreatobiliary (PB), and ambiguous (AM). The impact of adjuvant therapy on IHC subtype and disease stage is unclear. W
Autor:
Matthew P. Holtzman, Melissa E. Hogg, J. Wallis Marsh, David L. Bartlett, James F. Pingpank, Mashaal Dhir, Amer H. Zureikat, David A. Geller, M. Haroon A. Choudry, Herbert J. Zeh, Heather L. Jones, Mazen S. Zenati, Nathan Bahary, Allan Tsung
Publikováno v:
Annals of Surgical Oncology. 25:550-557
In the era of modern effective systemic chemotherapy, the comparative effectiveness of hepatic artery infusion (HAI) versus selective internal radiation therapy (yttrium-90 [Y90]) for pretreated patients with isolated unresectable colorectal liver me
Autor:
Jennifer Steve, Heather L. Jones, Mazen S. Zenati, Samantha Perkins, James F. Pingpank, Melissa E. Hogg, Haroon A. Choudry, Herbert J. Zeh, David L. Bartlett, Mashaal Dhir, Amber K. Clifford, Matthew P. Holtzman, Amer H. Zureikat, James C. Padussis
Publikováno v:
Journal of Surgical Oncology. 114:342-347
Background Hepatic artery infusion (HAI) chemotherapy can be combined with systemic chemotherapy for the treatment of isolated unresectable colorectal liver metastases (IU-CRLM) and intrahepatic cholangiocarcinoma (U-ICC). However, HAI pump placement
Autor:
V.M. Kim, Susannah G. Ellsworth, Amer H. Zureikat, Nathan Bahary, Kenneth K. Lee, Richard S. Hoehn, Aatur D. Singhi, A.Y. Hammad, Alessandro Paniccia, Samer AlMasri, Mazen S. Zenati
Publikováno v:
HPB. 23:S504
Publikováno v:
Annals of surgical oncology. 25(7)
National adherence to treatment guidelines for pancreatic ductal adenocarcinoma (PDAC) is a concern. This study aims to evaluate national expected treatment (ET) adherence for all PDAC stages. We hypothesized that both patient and hospital demographi
Autor:
Ahmad Hamad, Amer H. Zureikat, Nathan Bahary, Mazen S. Zenati, Jennifer Steve, Kenneth K. Lee, Irene Epelboym, Melissa E. Hogg, Herbert J. Zeh
Publikováno v:
Annals of surgical oncology. 24(9)
Receipt of 6 cycles of adjuvant chemotherapy (AC) is standard of care in pancreatic cancer (PC). Neoadjuvant chemotherapy (NAC) is increasingly utilized; however, optimal number of cycles needed alone or in combination with AC remains unknown. We sou
Autor:
Kenneth K.W. Lee, David L. Bartlett, James F. Pingpank, Amer H. Zureikat, Haroon A. Choudry, Matthew P. Holtzman, Mazen S. Zenati, Lekshmi Ramalingam, Heather Jones, Herbert J. Zeh, Joshua Winer, Steven A. Ahrendt
Publikováno v:
Annals of Surgical Oncology. 21:1456-1462
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) for peritoneal carcinomatosis (PC) of colorectal origin increases survival (OS) compared to systemic chemotherapy alone. Signet ring histology demonstrates aggressive